In 2023, around 6.0 million of blood pressure monitors worth 11.9 billion rubles (retail prices, VAT included) were sold on the offline and online retail markets in Russia. The sales went up 29% in physical and up 10% in monetary terms. At the same time, the average price dropped—it was 1,970 rubles in 2023 against 2,310 in 2022. While the prices for this category of medical equipment in 2023 dropped 5% from 2022, the inflation rate in Q1 2024 was 2.7% against Q1 2023.

In Q1 2024, the Russian pharmaceutical market had 1.4 billion packages of drugs on sale, up 2.4% from Q1 2023. Throughout 2023, 5.88 billion packages entered the market, and in 2022, around 5.95 billion. Despite the volume decreasing in physical terms, the range of medicines is expanding. In 2023, more than 15,000 SKU (stock keeping units) of pharmaceutical drugs were put into circulation, up 548 from 2022 (Fig. 1).

In Q1 2024, Russia-based manufacturers produced 193.1 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 13.8% from Q1 2023. In physical terms, 993 million packages were manufactured, up 1.4% from January–March 2023, or 19.9 billion minimum dosage units (MDU), up 4.1%.

In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The highest price growth rates were seen in early 2023 (Fig. 1); as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023. By the end of the year, the prices had stabilized, dropping to a year-low. January 2024, however, saw a slight upward trend (26.4%), which continued in February 2024 (28.6%). In January–February 2024, the price index was 26.9%.

In January–February 2024, Russian manufacturers produced 124.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 22.8% from the same period in 2023. In physical terms, it was 649 million packages, up 6.4% from January–February 2023. If calculated in minimum dosage units (MDU), the manufacture was 13.2 billion, up 10.8% from the same periods in 2023.

In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The highest price growth rates were seen in early 2023; as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023. By the end of the year, the prices had stabilized, dropping to a year-low. January 2024, however, saw a slight upward trend; the price index was 26.4% from January 2023.

49.2% of Russian physicians fully support the initiative to allow doctors working in private medical institutions early retirement, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.

Most Russian physicians remain pessimistic regarding the new system of remuneration. Only 9.6% of the doctors expect higher salaries soon, saying that the chances of implementing the project are high, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. Another 15.7% of the respondents believe that the system will be launched only if the economic situation improves. Finally, 21.6% do not expect any rapid changes, saying that even if it is launched as quickly as possible, it will take several years before the system launches nationwide.

Most Russian physicians (52.8%) support the suspension of ICD-11 implementation in the country, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. In particular, 34.4% fully support the suspension, believing that a number of ICD-11 sections promote the LGBT agenda and contradict medical science. Another 18.4%, while saying that the suspension of ICD-11 in its current form may be appropriate, believe that the implementation can be resumed provided that the controversial sections are excluded.

Most Russian physicians (52.8%) support the suspension of ICD-11 implementation in the country, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. In particular, 34.4% fully support the suspension, believing that a number of ICD-11 sections promote the LGBT agenda and contradict medical science. Another 18.4%, while saying that the suspension of ICD-11 in its current form may be appropriate, believe that the implementation can be resumed provided that the controversial sections are excluded.